Table 4 Clinical characteristics before and after PSM
Before PSM | After PSM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mixed cell adenocarcinoma | Serous cystadenocarcinoma | p | Papillary serous cystadenocarcinoma | p | Serous cystadenocarcinoma | p | Papillary serous cystadenocarcinoma | p | ||
n | 2019 | 10790 | 7949 | 2019 | 2019 | |||||
Age | (mean (SD)) | 57.90 (12.42) | 61.88 (12.07) | <0.001 | 61.52 (12.57) | <0.001 | 58.07 (12.37) | 0.66 | 58.53 (12.60) | 0.109 |
Grade (%) | Well differentiated | 183 ( 9.1) | 356 ( 3.3) | <0.001 | 365 ( 4.6) | <0.001 | 191 ( 9.5) | 0.087 | 135 ( 6.7) | 0.023 |
Moderately differentiated | 381 (18.9) | 944 ( 8.7) | 1313 (16.5) | 322 (15.9) | 359 (17.8) | |||||
Poorly differentiated | 903 (44.7) | 5163 (47.8) | 4204 (52.9) | 955 (47.3) | 946 (46.9) | |||||
Undifferentiated | 552 (27.3) | 4327 (40.1) | 2067 (26.0) | 551 (27.3) | 579 (28.7) | |||||
SEER stage (%) | Localized | 389 (19.3) | 541 ( 5.0) | <0.001 | 354 ( 4.5) | <0.001 | 413 (20.5) | 0.386 | 353 (17.5) | 0.323 |
Regional | 685 (33.9) | 1906 (17.7) | 1245 (15.7) | 647 (32.0) | 710 (35.2) | |||||
Distant | 945 (46.8) | 8343 (77.3) | 6350 (79.9) | 959 (47.5) | 956 (47.4) | |||||
AJCC stage (%) | Stage I | 698 (34.6) | 1010 ( 9.4) | <0.001 | 706 ( 8.9) | <0.001 | 699 (34.6) | 0.99 | 671 (33.2) | 0.631 |
Stage II | 302 (15.0) | 945 ( 8.8) | 627 ( 7.9) | 297 (14.7) | 329 (16.3) | |||||
Stage III | 754 (37.3) | 5954 (55.2) | 4481 (56.4) | 762 (37.7) | 758 (37.5) | |||||
Stage IV | 265 (13.1) | 2881 (26.7) | 2135 (26.9) | 261 (12.9) | 261 (12.9) |